Venus Medtech (Hangzhou) (HKSE:02500) EPS (Basic) : HK$-1.76 (TTM As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Venus Medtech (Hangzhou) EPS (Basic)?

Venus Medtech (Hangzhou)'s basic earnings per share (Basic EPS) for the six months ended in Dec. 2023 was HK$-0.89. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-1.76.

Venus Medtech (Hangzhou)'s EPS (Diluted) for the six months ended in Dec. 2023 was HK$-0.89. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-1.76.

Venus Medtech (Hangzhou)'s EPS without NRI for the six months ended in Dec. 2023 was HK$-1.37. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2023 was -2.22.

During the past 3 years, the average EPS without NRI Growth Rate was -47.80% per year. During the past 5 years, the average EPS without NRI Growth Rate was -24.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 7 years, Venus Medtech (Hangzhou)'s highest 3-Year average EPS without NRI Growth Rate was -13.30% per year. The lowest was -47.80% per year. And the median was -25.45% per year.

Venus Medtech (Hangzhou) EPS (Basic) Historical Data

The historical data trend for Venus Medtech (Hangzhou)'s EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Venus Medtech (Hangzhou) EPS (Basic) Chart

Venus Medtech (Hangzhou) Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EPS (Basic)

Get a 7-Day Free Trial

-1.36

-0.53

-1.04

-2.70

-1.76

Venus Medtech (Hangzhou) Semi-Annual Data
	Dec17	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EPS (Basic)	Get a 7-Day Free Trial							-0.72	-0.54	-2.19	-0.88	-0.89

Venus Medtech (Hangzhou) EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Venus Medtech (Hangzhou)'s Basic EPS for the fiscal year that ended in Dec. 2023 is calculated as

Basic EPS (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-769.751	-	0)	/	437.897
	=	-1.76

Venus Medtech (Hangzhou)'s Basic EPS for the quarter that ended in Dec. 2023 is calculated as

Basic EPS (Q: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-386.723	-	0)	/	437.897
	=	-0.88

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-1.76

Venus Medtech (Hangzhou) (HKSE:02500) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Venus Medtech (Hangzhou) EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Venus Medtech (Hangzhou)'s EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

Venus Medtech (Hangzhou) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Venus Medtech (Hangzhou) Inc (HKSE:02500) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 88, Jiangling Road, Room 311, 3rd Floor, Block 2, Binjiang District, Hangzhou, CHN, 310051

Website

https://www.venusmedtech.com

Venus Medtech (Hangzhou) Inc is engaged in the development and commercialization of transcatheter solutions for structural heart diseases. It has two TAVR products on the market, namely VenusA-Valve, and VenusA-Plus. VenusA-Valve is its first-generation TAVR device, which is used to treat severe Aortic Stenosis (AS) using a transcatheter approach. VenusA-Plus is an upgraded product of VenusA-Valve. Geographically all of the revenue is derived from Mainland China.

Executives

Zeng Min Frank	2201 Interest of corporation controlled by you
Zi Zhenjun	2201 Interest of corporation controlled by you
Ming Zhi Investments (bvi) Limited	2101 Beneficial owner
Ming Zhi Investments Limited	2201 Interest of corporation controlled by you
Qiming Venture Partners Iii, L.p.	2201 Interest of corporation controlled by you
Qiming Corporate Gp Iii, Ltd.	2201 Interest of corporation controlled by you
Qiming Gp Iii, L.p.	2201 Interest of corporation controlled by you
Dcp Capital Partners, L.p.	2201 Interest of corporation controlled by you
Dcp General Partner, Ltd	2201 Interest of corporation controlled by you
Dcp, Ltd.	2201 Interest of corporation controlled by you
Liu Haifeng David	2201 Interest of corporation controlled by you
Muheng Capital Partners (hong Kong) Limited	2101 Beneficial owner
Red Giant Limited	2201 Interest of corporation controlled by you
Wolhardt Julian Juul	2201 Interest of corporation controlled by you
Horizon Binjiang Llc	2101 Beneficial owner

Venus Medtech (Hangzhou) Headlines

No Headlines